Literature DB >> 24141039

Chronic cholestatic liver diseases: clues from histopathology for pathogenesis.

Marion J Pollheimer1, Peter Fickert2, Bruno Stieger3.   

Abstract

Chronic cholestatic liver diseases include fibrosing cholangiopathies such as primary biliary cirrhosis or primary sclerosing cholangitis. These and related cholangiopathies clearly display pathologies associated with (auto)immunologic processes. As the cholangiocyte's apical membrane is exposed to the toxic actions of the bile fluid, the interaction of bile with cholangiocytes and the biliary tree in general must be considered to completely understand the pathogenesis of cholangiopathies. While the molecular processes involved in the hepatocellular formation of bile are well understood in both normal and pathophysiologic conditions, those in the bile ducts of normal liver and in livers with cholangiopathies lag behind. This survey highlights key mechanisms known to date that are important for the formation of bile by hepatocytes and its modification by the biliary tree. It also delineates the clinical pathophysiologic findings for cholangiopathies and puts them in perspective with current experimental models to reveal the pathogenesis of cholangiopathies and develop novel therapeutic approaches.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal models; Cholangiopathies; Cholestasis; Liver fibrosis; Primary biliary cirrhosis; Primary sclerosing cholangitis

Mesh:

Year:  2013        PMID: 24141039     DOI: 10.1016/j.mam.2013.10.001

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  17 in total

1.  Role of Inflammatory and Oxidative Stress, Cytochrome P450 2E1, and Bile Acid Disturbance in Rat Liver Injury Induced by Isoniazid and Lipopolysaccharide Cotreatment.

Authors:  Hozeifa Mohamed Hassan; Hongli Guo; Bashir Alsiddig Yousef; Mounia Guerram; Aida Mejda Hamdi; Luyong Zhang; Zhenzhou Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

2.  Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.

Authors:  Dongke Yu; Shi-Ying Cai; Albert Mennone; Pamela Vig; James L Boyer
Journal:  Liver Int       Date:  2018-02-13       Impact factor: 5.828

Review 3.  Secondary Sclerosing Cholangitis in Critically Ill Patients: An Underdiagnosed Entity.

Authors:  Pedro Martins; Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2019-07-30

Review 4.  A shift in paradigm towards human biology-based systems for cholestatic-liver diseases.

Authors:  Fozia Noor
Journal:  J Physiol       Date:  2015-11-04       Impact factor: 5.182

Review 5.  Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.

Authors:  Jiao-Ya Xu; Zhong-Ping Li; Li Zhang; Guang Ji
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

6.  Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.

Authors:  Shi-Ying Cai; Dongke Yu; Carol J Soroka; Jing Wang; James L Boyer
Journal:  J Hepatol       Date:  2020-10-09       Impact factor: 25.083

Review 7.  The role of bile acids in cholestatic liver injury.

Authors:  Shi-Ying Cai; James L Boyer
Journal:  Ann Transl Med       Date:  2021-04

Review 8.  Recent advances in understanding hepatic drug transport.

Authors:  Bruno Stieger; Bruno Hagenbuch
Journal:  F1000Res       Date:  2016-10-06

Review 9.  Role of (drug) transporters in imaging in health and disease.

Authors:  Bruno Stieger; Jashvant D Unadkat; Bhagwat Prasad; Oliver Langer; Hariprasad Gali
Journal:  Drug Metab Dispos       Date:  2014-09-23       Impact factor: 3.922

10.  Notch Signaling Coordinates Progenitor Cell-Mediated Biliary Regeneration Following Partial Hepatectomy.

Authors:  Jie Lu; Yingqun Zhou; Tianyuan Hu; Hui Zhang; Miao Shen; Ping Cheng; Weiqi Dai; Fan Wang; Kan Chen; Yan Zhang; Chengfeng Wang; Jingjing Li; Yuanyuan Zheng; Jing Yang; Rong Zhu; Jianrong Wang; Wenxia Lu; Huawei Zhang; Junshan Wang; Yujing Xia; Thiago M De Assuncao; Nidhi Jalan-Sakrikar; Robert C Huebert; Chuanyong Guo
Journal:  Sci Rep       Date:  2016-03-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.